Roche's Tocilizumab Subcutaneous Injection Receives New Indication Approval in China

Today, the official website of NMPA announced that the new indication marketing application for tocilizumab injection (subcutaneous injection) submitted by Roche has been approved. Public information indicates that tocilizumab is an anti-IL-6R recombinant humanized monoclonal antibody, and this drug has already been approved in China for various indications. The specific indication for this approval has not yet been found in public sources.

Screenshot source: NMPA official website

Public data shows that tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody expressed in mammalian cells (CHO). It functions by inhibiting the activity of the IL-6 receptor. IL-6 is a pro-inflammatory cytokine, and its release can trigger a series of downstream pro-inflammatory responses. Tocilizumab inhibits IL-6 signal transduction by blocking the binding of IL-6 to both soluble and membrane-bound IL-6 receptors, thereby reducing pathological inflammatory responses.

Roche's official website shows that tocilizumab has been approved for multiple indications worldwide, including rheumatoid arthritis (RA), pediatric juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), giant cell arteritis (GCA), and CAR-T cell-induced cytokine release syndrome (CRS), among others.